AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6502494 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral milrinone
Number of subjects: 39
Study 6502494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 39
Study 6502494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study 30238650 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention using teach-back, including individual teaching session, heart failure booklet, weighing scales, diary for daily weight, follow-up phone call 2 weeks after discharge.
Number of subjects: 140
Study 30238650 — intervention group
Group type: COMPARATOR
Intervention: Usual education plus heart failure booklet (control group).
Number of subjects: 140
Study 28036350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8MM probe‐CMA test
Number of subjects: 0
Study 28036350 — intervention group
Group type: COMPARATOR
Intervention: CMA testing
Number of subjects: 0
Study 25446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib (1000 mg/m2 once weekly for 7 weeks + 1 week rest, then once every 3 weeks + 1 week rest)
Number of subjects: 102
Study 25446376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 25446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sorafenib
Number of subjects: 102
Study 25446376 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 102
Study 25446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 102
Study 25446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-foot syndrome (HFS)
Number of subjects: 102
Study 25446376 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of PDGFRβ expression
Number of subjects: 102
Study 22440125 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in urinary albumin excretion (UAE) of 2 logs at 1 year
Number of subjects: 393
Study 22440125 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in urinary albumin excretion (UAE) of 2 logs at 1 year
Number of subjects: 393
Study 20237316 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance
Number of subjects: 294
Study 20237316 — intervention group
Group type: COMPARATOR
Intervention: Intense pregnancy surveillance alone
Number of subjects: 294
Study 18617121 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple nerve stimulation (radial, median, and musculocutaneous nerves)
Number of subjects: 60
Study 18617121 — intervention group
Group type: COMPARATOR
Intervention: Radial plus musculocutaneous nerve stimulation
Number of subjects: 60
Study 18617121 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple nerve stimulation
Number of subjects: 60
Study 15809570 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 394
Study 15809570 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent time spent in moderate to vigorous physical activity (MVPA)
Number of subjects: 394
Study 15809570 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in light‐intensity physical activity
Number of subjects: 394
Study 12888186 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs (6.6 g/day)
Number of subjects: 28
Study 12888186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10588554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 0
Study 10588554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 0
Study 10588554 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 8577018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate at low pH (AL)
Number of subjects: 10
Study 8577018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate at high pH (AH)
Number of subjects: 10
Study 8577018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide at low pH (OL)
Number of subjects: 10
Study 8577018 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide at high pH (OH)
Number of subjects: 10
Study 2012087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine powder (8 g, twice daily)
Number of subjects: 83
Study 2012087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine bar (8 g, twice daily)
Number of subjects: 83
Study 6187322 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine manipulation
Number of subjects: 168
Study 6187322 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 168
Study 31910877 — intervention group
Group type: EXPERIMENTAL
Intervention: EBMeDS system (intervention group)
Number of subjects: 3815
Study 31910877 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3815
Study 31373112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis oil, applied two times per day for 2 months
Number of subjects: 34
Study 31373112 — intervention group
Group type: COMPARATOR
Intervention: Placebo, applied two times per day for 2 months
Number of subjects: 34
Study 31373112 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis oil
Number of subjects: 34
Study 31373112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28093029 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg mirtazapine
Number of subjects: 19
Study 28093029 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg quetiapine
Number of subjects: 19
Study 28093029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27143858 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (50 mEq/day)
Number of subjects: 16
Study 27143858 — intervention group
Group type: COMPARATOR
Intervention: High sodium diet (300 mEq/day)
Number of subjects: 16
Study 27143858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg
Number of subjects: 16
Study 25159241 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct peritoneal resuscitation (DPR) with peritoneal lavage using 2.5% DELFLEX
Number of subjects: 88
Study 25159241 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct peritoneal resuscitation (DPR)
Number of subjects: 88
Study 22306735 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V
Number of subjects: 98
Study 22306735 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with peripheral stem cell rescue
Number of subjects: 98
Study 22306735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive disease
Number of subjects: 98
Study 19581636 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 337
Study 19581636 — intervention group
Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 337
Study 17763111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion and active 4‐mg gum (AA)
Number of subjects: 608
Study 17763111 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bupropion and placebo gum (AP)
Number of subjects: 608
Study 17763111 — intervention group
Group type: COMPARATOR
Intervention: Placebo bupropion and placebo gum (PP)
Number of subjects: 608
Study 14768921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (n = 18)
Number of subjects: 40
Study 14768921 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (n = 18)
Number of subjects: 40
Study 14768921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Ropivacaine 0.2% and Bupivacaine 0.125%)
Number of subjects: 40
Study 11598360 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxy progesterone acetate (DMPA)
Number of subjects: 50
Study 11598360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal pre‐medication)
Number of subjects: 50
Study 11598360 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 50
Study 9740160 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible hemodialysis membranes (BCMs)
Number of subjects: 153
Study 9740160 — intervention group
Group type: COMPARATOR
Intervention: Bioincompatible hemodialysis membranes (BICM)
Number of subjects: 153
Study 9740160 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 153
Study 9740160 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliguria at onset of dialysis
Number of subjects: 153
Study 9740160 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score with BCMs in nonoliguric patients
Number of subjects: 153
Study 7804477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine with psyllium hydrophilic mucilloid (PHM) 5.1 g twice daily
Number of subjects: 27
Study 7804477 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine therapy (4 g twice daily)
Number of subjects: 27
Study 3049118 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 3049118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg
Number of subjects: 0
Study 3049118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol and nifedipine
Number of subjects: 0
Study 3049118 — intervention group
Group type: COMPARATOR
Intervention: Control (individual components)
Number of subjects: 0
Study 31898914 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Number of subjects: 0
Study 31898914 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle or use of statins
Number of subjects: 0
Study 31898914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter inserted at the proximal subparaneural location (n = 31)
Number of subjects: 63
Study 31094804 — intervention group
Group type: COMPARATOR
Intervention: Catheter inserted at the distal supraparaneural location (n = 32)
Number of subjects: 63
Study 31094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (proximal and distal)
Number of subjects: 63
Study 27131979 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified auriculotherapy (different points ear puncture with xylocaine without needles)
Number of subjects: 0
Study 27131979 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 25545026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 0.5mg once daily
Number of subjects: 0
Study 25545026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fingolimod 1.25mg once daily
Number of subjects: 0
Study 25545026 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular interferon β‐1a (IFNβ‐1a IM) 30 μg/mL once weekly
Number of subjects: 0
Study 23988084 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 0
Study 23988084 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 22146674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched water (1.0 liter per day for 12 weeks) in open-label trial
Number of subjects: 36
Study 22146674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-enriched water (0.5 liter per day for 8 weeks) in double-blind trial
Number of subjects: 36
Study 22146674 — intervention group
Group type: COMPARATOR
Intervention: Placebo water in double-blind trial
Number of subjects: 36
Study 19248104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% MQX-503 gel
Number of subjects: 219
Study 19248104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 19248104 — intervention group
Group type: COMPARATOR
Intervention: MQX-503 and Placebo
Number of subjects: 219
Study 17087689 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational/Physical Therapy (OT/PT) intervention delivered via teletechnology or in-home visits
Number of subjects: 65
Study 17087689 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional home setting OT/PT sessions (trad group n = 16)
Number of subjects: 65
Study 17087689 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote OT/PT sessions via teletechnology (tele group n = 16)
Number of subjects: 65
Study 17087689 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 65
Study 15672958 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist ganirelix
Number of subjects: 0
Study 15672958 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist leuprolide acetate
Number of subjects: 0
Study 11397620 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg qd
Number of subjects: 10
Study 11397620 — intervention group
Group type: EXPERIMENTAL
Intervention: clarithromycin 500 mg bid
Number of subjects: 10
Study 11397620 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin 400 mg bid
Number of subjects: 10
Study 9310602 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg daily) plus weekly Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)
Number of subjects: 832
Study 9310602 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation plus weekly placebo
Number of subjects: 832
Study 9310602 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Deltaprim (malaria prophylaxis)
Number of subjects: 832
Study 9310602 — intervention group
Group type: COMPARATOR
Intervention: Malaria chemoprophylaxis
Number of subjects: 832
Study 8378244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride oral suspension (100 mg dose)
Number of subjects: 0
Study 8378244 — intervention group
Group type: COMPARATOR
Intervention: Plain solution (control)
Number of subjects: 0
Study 8378244 — intervention group
Group type: COMPARATOR
Intervention: Capsule (control)
Number of subjects: 0
Study 8378244 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride oral suspension
Number of subjects: 0
Study 3544660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine‐vasopressin (LVP)
Number of subjects: 50
Study 3544660 — intervention group
Group type: COMPARATOR
Intervention: Glypressin
Number of subjects: 50
Study 30951785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-bioglass complex (CB)
Number of subjects: 64
Study 30951785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan-bioglass slurry (CBS)
Number of subjects: 64
Study 30951785 — intervention group
Group type: COMPARATOR
Intervention: Standard remineralisation solution (RS)
Number of subjects: 64
Study 30951785 — intervention group
Group type: COMPARATOR
Intervention: Deionised water (NC)
Number of subjects: 64
Study 29587801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangguixu-san (DS)
Number of subjects: 48
Study 29587801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25629790 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg once daily
Number of subjects: 154
Study 25629790 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 154
Study 25629790 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 154
Study 24664172 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1 g orally each day for 2 months
Number of subjects: 30
Study 24664172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG monotherapy
Number of subjects: 621
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG+VPA
Number of subjects: 621
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG+PHT
Number of subjects: 621
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG+PB
Number of subjects: 621
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG+CBZ
Number of subjects: 621
Study 22466551 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG+inducers
Number of subjects: 621
Study 19752279 — intervention group
Group type: EXPERIMENTAL
Intervention: AHM (Anti-Hantaan virus monoclonal antibody) at doses of 2.5 to 20 mg
Number of subjects: 88
Study 19752279 — intervention group
Group type: EXPERIMENTAL
Intervention: AHM (Anti-Hantaan virus monoclonal antibody)
Number of subjects: 88
Study 17290062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 288
Study 17290062 — intervention group
Group type: COMPARATOR
Intervention: Usual supportive care
Number of subjects: 288
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients
Number of subjects: 64
Study 15386328 — intervention group
Group type: COMPARATOR
Intervention: Control group (benign breast tumours)
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with oestrogen receptor-negative tumours
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with poorly differentiated tumours
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with more advanced primary tumour stage
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with involved lymph nodes
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with distant metastases
Number of subjects: 64
Study 15386328 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer patients with more advanced TNM stage
Number of subjects: 64
Study 11286848 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2 (with simultaneous IM‐MS irradiation)
Number of subjects: 32
Study 11286848 — intervention group
Group type: COMPARATOR
Intervention: Arm 1 (without simultaneous IM‐MS irradiation)
Number of subjects: 32
Study 11286848 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal IM‐MS irradiation
Number of subjects: 32
Study 7974045 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-milk and premature formula (550 mg calcium and 300 mg phosphorus)
Number of subjects: 53
Study 7974045 — intervention group
Group type: COMPARATOR
Intervention: Breast-milk only
Number of subjects: 53
Study 2493710 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 0.2 mg intravenously, followed by increments of 0.1 mg at 60 s intervals until eye opening
Number of subjects: 40
Study 2493710 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.2 mg/kg, vecuronium bromide 0.1 mg/kg intravenously, and 3 vol.% isoflurane in oxygen for induction; nitrous oxide 66% in oxygen and 0.9 vol.% isoflurane for maintenance
Number of subjects: 40
Study 30394344 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of rectal misoprostol before cesarean section
Number of subjects: 120
Study 30394344 — intervention group
Group type: COMPARATOR
Intervention: 400 μg of rectal misoprostol after cesarean section
Number of subjects: 120
Study 27044318 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless approach with enamel matrix derivative (EMD) proteins
Number of subjects: 30
Study 27044318 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive surgery (MIST) with enamel matrix derivative (EMD) proteins
Number of subjects: 30
Study 25708866 — intervention group
Group type: EXPERIMENTAL
Intervention: niacin 6000 mg/day
Number of subjects: 9
Study 25708866 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 22739330 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-WBV (exercise with whole-body vibration)
Number of subjects: 32
Study 22739330 — intervention group
Group type: COMPARATOR
Intervention: EX (exercise without whole-body vibration)
Number of subjects: 32
Study 21321039 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate abduction treatment (6 weeks)
Number of subjects: 128
Study 21321039 — intervention group
Group type: COMPARATOR
Intervention: Active sonographic surveillance
Number of subjects: 128
Study 19922671 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Resistance (IR) assessed by HOMA-IR
Number of subjects: 1168
Study 19922671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1168
Study 16958567 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day MPH administered in five different paradigms
Number of subjects: 48
Study 16958567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12612308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 24
Study 12612308 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24
Study 12612308 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy subjects)
Number of subjects: 24
Study 12612308 — intervention group
Group type: COMPARATOR
Intervention: Control (Asthmatic subjects)
Number of subjects: 24
Study 10690818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerocorneal tunnel incision
Number of subjects: 100
Study 10690818 — intervention group
Group type: COMPARATOR
Intervention: Clear corneal tunnel incision
Number of subjects: 100
Study 9146851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery of acetylcholine via iontophoresis (150 microA for 40 s) at various sites in the forearm and hand
Number of subjects: 13
Study 9146851 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline microcirculation flow recorded by laser Doppler fluxmetry (LDF)
Number of subjects: 13
Study 8180458 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted fast spin-echo (FSE) imaging
Number of subjects: 100
Study 8180458 — intervention group
Group type: COMPARATOR
Intervention: T2-weighted conventional spin-echo (CSE) imaging
Number of subjects: 100
Study 2834115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin pretreatment (5000 IU IV before exercise)
Number of subjects: 10
Study 2834115 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 10
Study 31302075 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection (PAAI)
Number of subjects: 55
Study 31302075 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 55
Study 31302075 — intervention group
Group type: EXPERIMENTAL
Intervention: PAAI
Number of subjects: 55